We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-4.33%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.5B
AUM Growth
-$794M
Cap. Flow
+$217M
Cap. Flow %
1.89%
Top 10 Hldgs %
81.68%
Holding
128
New
8
Increased
22
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$146M
2
ABLX
Ablynx NV
ABLX
+$94M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$73M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$54.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$45M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$170M
2
AKAO
Achaogen Inc
AKAO
+$47.2M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$22.2M
4
EXEL icon
Exelixis
EXEL
+$15.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 93.21%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
76
Corbus Pharmaceuticals
CRBP
$166M
$4.69M 0.04%
+22,024
New +$4.71M
ECYT
77
DELISTED
Endocyte, Inc. Common Stock
ECYT
$4.65M 0.04%
+1,087,323
New +$5.18M
AAAP
78
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$4.5M 0.04%
55,125
-2,188,137
-98% -$170M
ACOR
79
DELISTED
Acorda Therapeutics
ACOR
$4.42M 0.04%
1,716
-2,613
-60% -$7.43M
IFRX icon
80
InflaRx
IFRX
$245M
$4.19M 0.04%
+200,000
New +$3.61M
OVID icon
81
Ovid Therapeutics
OVID
$424M
$3.29M 0.03%
333,333
– –
ARAV
82
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.14M 0.03%
237,718
-1,818
-0.8% -$23.4K
AKTX
83
Akari Therapeutics
AKTX
$14.8M
$3.02M 0.03%
871
+250
+40% +$964K
TRIL
84
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.97M 0.03%
409,323
-4,374
-1% -$36.2K
EPZM
85
DELISTED
Epizyme, Inc
EPZM
$2.92M 0.03%
232,481
– –
RNAC icon
86
Cartesian Therapeutics
RNAC
$215M
$2.78M 0.02%
9,457
-203
-2% -$88.7K
VIRX
87
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.74M 0.02%
21,190
– –
NVAX icon
88
Novavax
NVAX
$1.21B
$2.48M 0.02%
100,000
– –
TNXP icon
89
Tonix Pharmaceuticals
TNXP
$154M
– –
0
– –
KRYS icon
90
Krystal Biotech
KRYS
$10.6B
$2.1M 0.02%
200,000
– –
KPTI icon
91
Karyopharm Therapeutics
KPTI
$155M
$2.08M 0.02%
14,466
– –
NTRA icon
92
Natera
NTRA
$35.8B
$2.06M 0.02%
228,676
– –
TRVN
93
DELISTED
Trevena, Inc.
TRVN
$1.52M 0.01%
1,520
– –
RARX
94
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.51M 0.01%
177,952
– –
CLLS
95
Cellectis
CLLS
$287M
$1.46M 0.01%
50,000
– –
DVAX
96
DELISTED
Dynavax Technologies
DVAX
$1.4M 0.01%
75,000
– –
AKAO
97
DELISTED
Achaogen Inc
AKAO
$1.31M 0.01%
122,482
-3,764,396
-97% -$47.2M
JNCE
98
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.27M 0.01%
100,000
– –
INFI
99
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.18M 0.01%
580,400
– –
MDWD icon
100
MediWound
MDWD
$186M
$1.01M 0.01%
32,286
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Baker Bros. Advisors held 128 positions worth $11.5B, down 6.4% from $12.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors's Q4 2017 filing shows 8 new, 22 increased, 12 reduced and 5 closed positions. Its largest new stake was Ablynx NV: 4,161,118 shares worth $104M. The largest sale was Advanced Accelerator Applications S.A., an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q4 2017 buy was Ablynx NV: 4,161,118 shares worth $104M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $146M increase.
  • Baker Bros. Advisors's biggest Q4 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $170M.
  • Baker Bros. Advisors fully exited NeuroDerm Ltd. Ordinary Shares in Q4 2017, selling an estimated $22.2M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $11.5B portfolio in Q4 2017.
  • Baker Bros. Advisors opened 8 new positions and closed 5 in Q4 2017.
  • Baker Bros. Advisors's portfolio value fell 6.4% quarter-over-quarter to $11.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.